RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $232
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Craig Wong-Pan maintains a Sector Perform rating on ResMed (NYSE:RMD) and raises the price target from $224 to $232.
October 25, 2024 | 5:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained its Sector Perform rating on ResMed and increased the price target from $224 to $232, indicating a positive outlook.
The increase in price target from $224 to $232 by RBC Capital suggests a positive outlook for ResMed, which could lead to a short-term increase in stock price. The maintained Sector Perform rating indicates steady performance expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100